(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/121327 A1

(51) International Patent Classification:
C07D 403/04 (2006.01) *A61K 31/407* (2006.01)
C07D 403/14 (2006.01) *A61P 35/00* (2006.01)
C07D 471/10 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/CN2020/137266

(22) International Filing Date:
17 December 2020 (17.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2019/126760
19 December 2019 (19.12.2019) CN
62/961,775 16 January 2020 (16.01.2020) US
PCT/CN2020/126595
04 November 2020 (04.11.2020) CN

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(71) Applicant *(for SC only)*: **JOHNSON & JOHNSON (CHINA) INVESTMENT LTD.** [CN/CN]; 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN).

(72) Inventors: **CAI, Wei**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **DAI, Xuedong**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **QUEROLLE, Olivier Alexis Georges**; Janssen-Cilag, 1 Rue Camille Desmoulins, TSA 91003, 92787 Issy-les Moulineaux Cedex 9 (FR). **THURING, Johannes Wilhelmus John F**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **LIU, Yingtao**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **LIU, Lianzhu**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **XU, Yanping**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **FU, Liqiang**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **LI, Ming**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **FANG, Lichao**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **DENG, Xiangjun**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing

(54) Title: SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES

(57) Abstract: Provided herein are pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.




Figure 1

WO 2021/121327 A1

[Continued on next page]

Road, Xuhui District, Shanghai 200233 (CN). **ZHAO, Qiwu**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **LI, Kangying**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **NG, Alicia Tee Fuay**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **DARVILLE, Nicolas Freddy J**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **CLEATOR, Edward**; Janssen-Cilag Ltd, 50-100 Holmers Farm Way, High Wycombe Buckinghamshire HP12 4EG (GB). **URBANIETZ, Gregor Thomas**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **MATON, William, Marc**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) **Agent: NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD.**; 10th Floor, Tower C, Beijing Global Trade Center, 36 North Third Ring Road East, Dongcheng District, Beijing 100013 (CN).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*